AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 43 min read$GDRX

GoodRx Earnings: What To Look For From GDRX

GoodRx (NASDAQ: GDRX) is set to report earnings Wednesday after the bell. The company reported $194 million revenue last quarter, down 4.4% year over year, and slightly topped full-year guidance versus analysts. For the upcoming quarter, analysts expect revenue to fall 4.7% year over year. The average analyst price target is $3.21 vs. $3.16.

Original reporting
financialcontent.com
Published Aug 4, 2026, 4:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 4, 2026, 4:38 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
GoodRx Earnings: What To Look For From GDRX — source image
Source · financialcontent.com
Decision brief

The 30-second read

$GDRXNeutralMed
01

Why it matters

This is an earnings preview that can drive positioning and implied volatility into the print. However, the text does not disclose new guidance, filings, or other primary catalysts beyond the earnings timing and expectation framing.

02

Market read

Traders can use the stated consensus revenue decline and the company’s recent pattern of missing revenue estimates to gauge risk into the earnings release.

03

What to watch

The article highlights revenue only; traders may need to focus on margins, cash flow, and any updated full-year guidance details that are not provided here.

Relevance 5/10Novelty 4/10Timing: pre-market into Wednesday after-the-bell earnings

Background

GoodRx (GDRX) is scheduled to report results Wednesday after the bell. The article frames the setup using the prior quarter’s revenue beat and the current consensus expectation for a year-on-year revenue decline.

Company-level read

Ticker impact

$GDRXNeutralMedium confidence
Context

GoodRx is set to report earnings Wednesday after the bell, with the article citing recent revenue trends and consensus expectations.

Expected impact

Likely elevated pre-earnings volatility; direction depends on whether reported revenue and guidance confirm or reverse the expected year-on-year decline.

Evidence & confidence

The article provides setup details (next report timing, prior quarter beat, and consensus revenue decline) but does not include any fresh company-specific disclosure beyond what is already framed as expectations.

Market effects

Sector

Healthcare tech sentiment may hinge on whether GoodRx can sustain revenue momentum versus peers, but the piece does not add new sector fundamentals.

Regional

Primarily US-focused given the NASDAQ-listed subject and after-the-bell catalyst.

Global

Limited, as the article is company-specific earnings setup without cross-border policy or supply-chain developments.

Counterpoint

What could challenge this read

If the market has already priced in a revenue decline, a modest beat or firmer guidance could outperform expectations even without major upside growth.

Key entities

  • company
    GoodRx

    NASDAQ-listed healthcare tech company scheduled to report earnings Wednesday after the bell.

  • company
    Omnicell

    Peer mentioned as having reported results already, with its stock down after beating revenue estimates.

Read at source← All news

Related articles

AUG 6
$OSCRMed

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

pymnts.com5 min
AUG 5
$GDRXHigh

GoodRx Holdings, Inc. (GDRX): Results of Operations and Financial Condition

GoodRx Holdings, Inc. (GDRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gdrxq226-exx991pressrelease.htm EX-99.1 GDRX Q2'26 - EX-99.1 (Press Release) Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2026 RESULTS Pharma Direct and Subscription Revenue Increased 76% and 39% , Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adj

SEC EDGAR 8-K6 min
JUL 13
$GDRXMed

GoodRx (GDRX) Stock Trades Up, Here Is Why

GoodRx (NASDAQ: GDRX) shares rose 2.6% after the company announced a partnership with Paytient to embed GoodRx’s prescription savings into employer-sponsored benefits. The integration is designed to offer lower cash prices at 70,000+ U.S. pharmacies. After the initial move, GDRX traded around $3.01, up 1.9%.

financialcontent.com4 min
JUN 9
$GDRXMedAI 8/10

GoodRx Holdings, Inc. (GDRX) Strengthens Recurring Revenue Base with Companion

GoodRx (NASDAQ:GDRX) launched GoodRx Companion, a $14.99/month subscription aimed at patients with chronic conditions. The service offers savings on more than 200 generic medications and discounts on certain dental services, and it charges $19 for telehealth visits for common issues. The company said it is intended to strengthen its recurring revenue base beyond individual prescription transactions.

finance.yahoo.com4 min
AUG 8
$GRNDMedAI 8/10

Grindr CEO makes stunning AI reveal that changes the dating game

Grindr CEO George Arison said the dating app is shifting to an AI-native approach, using AI coding tools and expecting AI token costs of about $6 million this year. In Q2, Grindr reported revenue of $138 million, up 33% year over year, beating an estimated $132 million, with paying users up 16% to 1.4 million. Full-year 2026 guidance was raised to about $540 million revenue and $232 million adjusted EBITDA.

yahoo.com6 min